Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells
Biol. Res
;
52: 7, 2019. graf
Artigo
em Inglês
| LILACS
| ID: biblio-1011410
ABSTRACT
BACKGROUND: Currently, the prognosis of patients with non-small cell lung cancer (NSCLC) remains dismal; hence, it is critical to identify effective anti-NSCLC agents with limited side effects. This study aimed to evaluate the therapeutic potential of flavonoid compound vitexin in human NSCLC cells and the underlying mechanisms. RESULTS: The experimental results indicated that vitexin reduced the viability of A549 cells in a dose-dependent manner with nearly no toxicity against normal human bronchial epithelial 16HBE cells. Vitexin also dose-dependently increased A549 cell apoptosis, accompanied by the decreased Bcl-2/Bax ratio and the increased expression of cleaved caspase-3. Moreover, the in vivo anticancer activity of vitexin was further determined in nude mice bearing A549 cells. In addition, vitexin induced the release of cytochrome c from the mitochondria to the cytosol and the loss of mitochondrial membrane potential. Vitexin also significantly reduced the levels of p-PI3K, p-Akt and p-mTOR, and the pro-apoptotic effect of vitexin on A549 cells was partly blocked by SC79, an Akt activator. CONCLUSIONS: Accordingly, we believed that vitexin could be used as a potential therapeutic agent for the treatment of NSCLC in the future.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Apoptose
/
Carcinoma Pulmonar de Células não Pequenas
/
Fosfatidilinositol 3-Quinases
/
Apigenina
/
Proteínas Proto-Oncogênicas c-akt
/
Serina-Treonina Quinases TOR
/
Neoplasias Pulmonares
/
Antineoplásicos
Limite:
Animais
/
Humanos
Idioma:
Inglês
Revista:
Biol. Res
Assunto da revista:
Biologia
Ano de publicação:
2019
Tipo de documento:
Artigo
País de afiliação:
China
Instituição/País de afiliação:
Affiliated Cancer Hospital of Zhengzhou University/CN
Similares
MEDLINE
...
LILACS
LIS